Testing empagliflozin for adults with type 2 diabetes on tablets
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how well and how safely empagliflozin works in real-world care for adults with type 2 diabetes who are not controlled on current pill treatment. Some participants take it with metformin, and the study helps confirm what to expect in everyday patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 65 and have type 2 diabetes.
- Your recent A1C (a blood sugar average) is between 7% and 10%.
- Your diabetes is not well controlled despite oral diabetes pills and lifestyle changes for at least 3 months.
- You have not taken empagliflozin before.
- Your kidney function (eGFR) is above 60.
- You can sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This trial compares two diabetes medications, empagliflozin and glimepiride, added to your current treatment to see which is more effective and safe for managing blood sugar. It is for adults with type 2 diabetes who have already been on oral diabetes pills for at least 8 weeks.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
Hear when a new Safety Issues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.